Industry calls on governments to invest more in antibiotics research

This article was published in Science Business 16 January 2020 by Florin Zubașcu. Alarm over the rise of antimicrobial resistance has prompted an increase in early stage research and led to the discovery of a number of new antibiotics, but for the pharmaceutical industry public investment overall remains at “concerning levels”, and more money needs […]
Antibiotics: Responsibly Making the Drugs Society Needs

This article was published in Pharma Boardroom on 13 November 2019. Opinion by Steve Brooks, Advisor to the AMR Industry Alliance.
Pharmaceuticals in the Environment

This article was published on PharmTech on 2 August, 2018 (Pharmaceutical Technology, Volume 42, Issue 8). Content by Sean Milmo. “An Antimicrobial Resistance (AMR) Industry Alliance, a global life-sciences coalition of more than 100 biotech, diagnostics, generic-drug, and research-based biopharmaceutical companies, has been combating AMR through work on the environment, as well as research, easing access […]
Antimicrobial resistance and vaccines – Life science industry makes the link and drives progress

This Q&A was first published on PharmExec on 20 April, 2018. Interview by Julian Upton. 1. When trying to reduce antimicrobial resistance, how can vaccines help?
NZZ – We need a sustainable business model

This interview was first published on NZZ on 24 February 2018. Interview by Birgit Voigt.
CGTN – Augmentation de la résistance antimicrobienne dans le monde

Garance Upham (Vice-President of World Against Antibiotic Resistance – WAAAR), Marc Sprenger Director WHO secretariat for antimicrobial resistance), Thomas Cueni (Chair of AMR Industry Alliance) explain the rise of antimicrobial resistance, the public health dangers and the measures that need to be taken to address it. Thomas Cueni explains that if we don’t find solutions […]
Antimicrobial Resistance The “Scariest” Public Health Issue, Needs Financial R&D Incentives, Industry Says

On the eve of the annual January World Health Organization Executive Board meeting, an alliance of pharmaceutical industries launched its first report on efforts made to curb antimicrobial resistance. The alliance also organised a conference on the report and on challenges of antimicrobial resistance, in particular the need for research and development incentives so that […]
Report tracks industry progress on drug resistance

A report today from an international association of life sciences companies suggests that the private sector is making progress in meeting its commitment to help solve the antimicrobial resistance (AMR) crisis, but much work remains. The progress report from the AMR Industry Alliance, a collection of more than 100 companies and trade associations representing the […]
Funding outlook shifts in fight against antimicrobial resistance

LONDON — Twenty-two research-based biopharmaceutical companies — including AstraZenica, GlaxoSmithKline and Merck — invested more than $2 billion in research and development to counter antimicrobial resistance in 2016, according to a survey released Thursday, potentially upending widespread perceptions that the private sector is trailing institutional donors in tackling AMR.
3 Questions with Thomas Cueni, Director General IFPMA, Chair, AMR Industry Alliance

Next week is crunch time for the Global Fund to Fight Aids, TB and Malaria. The agency, which channels donor money into lower-income, higher-burden countries for the world’s three big killer infectious diseases, is set to select a new executive director. After mis-steps in the spring that forced it to abandon and restart the process, […]